
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders
SAN DIEGO & BOSTON--(BUSINESS WIRE)--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs. Building on early success in Praxis's innovative Essential3 Program for Essential Tremor, SEQ.


















